Advertisement
U.S. markets closed
Advertisement

Senti Biosciences, Inc. (SNTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3606+0.0039 (+1.09%)
At close: 04:00PM EST
0.3531 -0.01 (-2.08%)
After hours: 07:07PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.3567
Open0.3590
Bid0.3660 x 1100
Ask0.3669 x 900
Day's Range0.3431 - 0.3789
52 Week Range0.2700 - 2.3700
Volume213,462
Avg. Volume2,613,050
Market Cap16.063M
Beta (5Y Monthly)2.52
PE Ratio (TTM)N/A
EPS (TTM)-1.9600
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SNTI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Senti Biosciences, Inc.
    Daily – Vickers Top Insider Picks for 03/13/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • GlobeNewswire

    Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

    – IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China – – Cash and receivables from GeneFab transaction expected to fund operations into Q4 2024 – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing

  • GlobeNewswire

    Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

    – Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced a new strategic collaborat

  • GlobeNewswire

    Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

    – Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform – SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (S